# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Citius Pharma (NASDAQ:CTXR) reported quarterly losses of $(0.06) per share which missed the analyst consensus estimate of $0.13...
National Cancer Institute (NCI)-designated research and treatment center City of Hope, in Duarte, CA, to participate in the Uni...
FDA assigns Prescription Drug User Fee Act (PDUFA) target action date of August 13, 2024
Net operating losses converted into non-dilutive capital
Citius Pharma (NASDAQ:CTXR) reported quarterly losses of $(0.06) per share. This is a 200 percent decrease over losses of $(0.0...
HC Wainwright & Co. analyst Vernon Bernardino reiterates Citius Pharma (NASDAQ:CTXR) with a Buy and maintains $4 price t...